Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




LabCorp to Acquire Certain Assets of Quest Diagnostics

By HospiMedica staff writers
Posted on 03 Mar 2003
Under an agreement made in early February 2003, Laboratory Corp. More...
of America (LabCorp, Burlington, NC, USA) agreed to pay US$4.5 million for certain assets of Quest Diagnostics (Teterboro, NJ, USA), following the completion of Quest's acquisition of Unilab Corp. (Tarzana, CA, USA). Quest's acquisition of Unilab for $813 million was recently approved by US regulators and is now completed.

The LabCorp purchase is designed to satisfy the concern of regulators that Quest's purchase of Unilab might harm competition of laboratory services in northern California. The assets LabCorp is acquiring include the leases for 46 patient service centers and contracts with independent physician associations in California (USA). LabCorp has been a pioneer in commercializing new diagnostic technologies and said it is the first US clinical laboratory to fully embrace genomic testing.

LabCorp combines its expertise in clinical testing technology with its Centers of Excellence. These include the Center for Molecular Biology and Pathology (Research Triangle Park, NC, USA), its National Genetics Institute in Los Angeles (CA, USA), its Center for Esoteric Testing (Burlington, NC, USA), and its ViroMed center in Minneapolis (MN, USA). The company had revenues of $2.2 billion in 2001.

"Strategically, the business acquired in this very important market also provides LabCorp with a solid foundation for generating additional revenues through both the routine physician market as well as business development activities in esoteric testing,” said Richard L. Novak, executive vice president and CEO of LabCorp.




Related Links:
LabCorp
Quest Diagnostics

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Urine Analyzer
respons® UDS100
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Adobe Stock

Blood Biomarkers Help Assess Growth Risks During Steroid Treatment in Duchenne Muscular Dystrophy

Children with Duchenne muscular dystrophy (DMD) commonly receive long-term corticosteroids to slow disease progression, but these drugs can impair linear growth and weaken bone. Understanding how specific... Read more

Molecular Diagnostics

view channel
Image: The Xpert Hemorrhagic Fever Panel test runs on Cepheid’s GeneXpert Dx systems (Photo courtesy of Cepheid)

WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response

The Democratic Republic of the Congo is confronting an Ebola Bundibugyo outbreak that the World Health Organization (WHO) designated a Public Health Emergency of International Concern on May 17, 2026.... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.